About Us

Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprietary technologies, we are developing a robust pipeline of AXC candidates with the potential to address unmet medical needs for new treatment options.

Our Technology


Zou Bin, Ph.D.

Chief Executive Officer

Zhong Chen

VP Biology

Bryan Yeung

VP Chemistry

Tan Ban Xiong

Director, Antibody

Tao Chun

Senior Director, Operations

Scientific Advisory Board

Paul Herrling

Kyriacos Costa Nicolaou

Board of Directors

Zou Bin, Ph.D.


Jack Yin Zheng, Ph.D.

Board Member

Thomas Keller, Ph.D.

Board Member